Tofisopam belongs to the benzodiazepine-related family but differs from classic benzodiazepines. Its anxiolytic effect is thought to arise from modulation of the GABA-A receptor complex in a way that reduces anxiety without producing marked sedation, muscle relaxation, or anticonvulsant activity. The exact molecular pathway is not fully defined, but research suggests a selective enhancement of inhibitory neurotransmission that lowers the central nervous system’s response to stressors.
In Hong Kong, these uses are not authorized; healthcare providers must follow local prescribing regulations.
Patients with any of these conditions should discuss alternative therapies with their clinician.
These effects are generally dose-related and may diminish with continued use.
This article provides educational information about tofisopam and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Tofisopam is primarily supplied as a 50 mg oral tablet. Some countries may offer other strengths, but the 50 mg pill is the most common formulation.
While some clinicians prescribe it off-label for panic-related anxiety, robust clinical trial data are limited. Use for panic attacks should only occur under close medical supervision.
Standard workplace or sports drug screens typically target controlled substances such as classic benzodiazepines. Because tofisopam is not a scheduled drug in most jurisdictions, it is seldom included in routine panels, but specialized testing can identify it if requested.
Unlike diazepam, tofisopam produces minimal sedation, muscle relaxation, or anticonvulsant effects. Its anxiolytic action is considered more selective, making it attractive for patients who need anxiety relief without pronounced drowsiness.
Take the missed tablet as soon as you remember, unless the next scheduled dose is within a few hours. Do not double the dose; maintain a regular dosing schedule as much as possible to avoid fluctuations in anxiety control.
Tofisopam tablets should be kept in a cool, dry place away from direct sunlight. Avoid storing them in areas that may exceed 30 °C for prolonged periods, such as a car trunk, to preserve potency.
Combining tofisopam with other central nervous system depressants-including OTC antihistamines or melatonin-may increase sedation. Discuss all concurrent medications with your pharmacist or physician before combining them.
Limited data exist on the transfer of tofisopam into breast milk. Because of the unknown risk to the infant, most guidelines advise against its use during lactation unless the benefit clearly outweighs potential harm.
Most patients notice a reduction in anxiety symptoms within 30 minutes to an hour after taking the first 50 mg tablet, though individual response times can vary.
Pricing differs by country and whether a generic version is available. In regions where tofisopam is marketed, it may be comparable to other prescription anxiolytics, but exact costs depend on local pharmacy pricing and insurance coverage.
